Deletion of Trp53 and Rb1 in Ctsk‐expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling. Issue 2 (22nd April 2022)

• Record Type: Journal Article
• Authors: Li, Yang; Yang, Shuting; Liu, Yang; Yang, Shuying
• Is Part Of: MedComm. Volume 3:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-22
• Subjects: bone -- Glut1 -- osteosarcoma -- Rb1 -- Trp53 -- YAP; 610
• DOI: 10.1002/mco2.131
• Languages: English
• ISSNs: 2688-2663

Abstract

Abstract: Glucose metabolism reprogramming is a critical factor in the progression of multiple cancers and is directly regulated by many tumor suppressors. However, how glucose metabolism regulates osteosarcoma development and progression is largely unknown. Cathepsin K (Ctsk) has been reported to express in chondroprogenitor cells and stem cells besides osteoclasts. Moreover, mutations in the tumor suppressors transformation‐related protein 53 (Trp53) and retinoblastoma protein (Rb1) are evident in approximately 50%–70% of human osteosarcoma. To understand how deletion of Trp53 and Rb1 in Ctsk‐expressing cells drives tumorigenesis, we generated the Ctsk‐Cre;Trp53 f/f /Rb1 f/f mouse model. Our data revealed that those mice developed osteosarcoma without formation of tumor in osteoclast lineage. The level of cortical bone destruction was gradually increased in parallel to the osteosarcoma progression rate. Through mechanistic studies, we found that loss of Trp53/Rb1 in Ctsk‐expressing cells significantly elevated Yes‐associated protein (YAP) expression and activity. YAP/TEAD1 complex binds to the glucose transporter 1 ( Glut1 ) promoter to upregulate Glut1 expression. Upregulated Glut1 expression led to overactive glucose metabolism, increasing osteosarcoma progression. Ablation of YAP signaling inhibited energy metabolism and delayed osteosarcoma progression in Ctsk‐Cre;Trp53 f/f /Rb1 f/f mice. Collectively, these findings provide proof of principle that inhibition of YAP activity may be a potential strategy for osteosarcoma treatment. Abstract :